Bortezomib extends survival of children with newly diagnosed T-cell lymphoblastic lymphoma
The addition of bortezomib to chemotherapy significantly improved survival outcomes among children and young adults with T-cell lymphoblastic lymphoma, according to phase 3 study results published in Journal of Clinical Oncology.